Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 27;62(8):e00533-18.
doi: 10.1128/AAC.00533-18. Print 2018 Aug.

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli

Suzannah M Schmidt-Malan  1 , Avisya J Mishra  1 , Ammara Mushtaq  1 , Cassandra L Brinkman  1 , Robin Patel  2   3
Affiliations

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli

Suzannah M Schmidt-Malan et al. Antimicrob Agents Chemother. .

Erratum in

Abstract

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam-β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n = 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/>128 μg/ml for imipenem alone to 0.25/1 μg/ml. For isolates harboring blaCTX-M (n = 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 μg/ml (83% susceptible). For isolates harboring blaCMY-2 (n = 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 μg/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

Keywords: Gram-negative bacilli; antimicrobial resistance.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vasoo S, Barreto JN, Tosh PK. 2015. Emerging issues in Gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 90:395–403. doi:10.1016/j.mayocp.2014.12.002. - DOI - PubMed
    1. Bornet C, Davin-Regli A, Bosi C, Pages J-M, Bollet C. 2000. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 38:1048–1052. - PMC - PubMed
    1. Syue LS, Chen YH, Ko WC, Hsueh PR. 2016. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents 47:250–258. doi:10.1016/j.ijantimicag.2015.12.021. - DOI - PubMed
    1. Pavez M, Vieira C, de Araujo MR, Cerda A, de Almeida LM, Lincopan N, Mamizuka EM. 2016. Molecular mechanisms of membrane impermeability in clinical isolates of Enterobacteriaceae exposed to imipenem selective pressure. Int J Antimicrob Agents 48:78–85. doi:10.1016/j.ijantimicag.2016.04.016. - DOI - PubMed
    1. Giancola SE, Mahoney MV, Bias TE, Hirsch EB. 2016. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manage 12:787–797. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources